Long-term perospirone treatment with a single dose at bedtime in schizophrenia: Relevant to intermittent dopamine D2 receptor antagonism

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 2, 2008, Pages 520-522

  Kusumi, Ichiro ^a   Masui, Takuya ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ID 15036; Intermittent D2 blockade; Maintenance; Perospirone; Plasma concentration; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRUG METABOLITE; ID 15036; PEROSPIRONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; MONOTHERAPY; SCHIZOPHRENIA;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; ISOINDOLES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, DOPAMINE D2; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES; TREATMENT OUTCOME;

EID: 38749130501     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.10.008     Document Type: Article

References (15)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth edition, Text revision (DSM-IV-TR) (2000), American Psychiatric Association, Washington, DC
2. 2 receptor occupancy by antipsychotics. Annual report of pharmacopsychiatry research 39 (2007), Mitsubishi Pharma Research Foundation 167-170
3. Boshes R.A., and Manschreck T.C. Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr Bull 28 (2002) 203-222
4. Carpenter W.T., Hanlon T.E., Heinrichs D.W., Summerfelt A.T., Kirkpatrick B., Levine J., et al. Continuous vs targeted medication in schizophrenia outpatients: outcome results. Am J Psychiatry 147 (2000) 1138-1148
5. Chan S.S.M., and Ungvari G.S. Maintenance therapy in schizophrenia: a critical comment. Int J Neuropsychopharmacol 5 (2002) 277-281
6. Gaebel W. Intermittent medication-an alternative?. Acta Psychiatrica Scand 89 suppl.382 (1994) 533-538
7. 2 receptor occupancy. Arch Gen Psychiatry 57 (2000) 553-559
8. Masui T., Kusumi I., Takahashi Y., and Koyama T. Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit 28 (2006) 73-75
9. Masui T., Kusumi I., Takahashi Y., and Koyama T. Effect of carbamazepine on the single oral dose pharmacokinetics of perospirone and its active metabolite. Prog Neuro-Psychopharmacol Biol Psychiatry 30 (2006) 1330-1333
10. 2, and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 251 (1993) 238-246
11. Mizuno Y., Tani N., Komuro S., Kanamaru H., and Nakatsuka I. In vitro metabolism of perospirone in rat, monkey, and human liver microsomes. Eur J Drug Metab Pharmacokinet 28 (2003) 59-65
12. 2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. J Neural Transm 105 (1998) 181-191
13. Togo T., Iseki E., Shoji M., Oyama I., Kase A., Uchikado H., et al. Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone. J Pharmacol Sci 91 (2003) 259-262
14. Yasui-Furukori N., Inoue Y., and Tateishi T. Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. J. Chromatography B 789 (2003) 239-245
15. Yasui-Furukori N., Furukori H., Nakagami T., Saito M., Inoue Y., Kaneko S., et al. Steady-state pharmacolkinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit 26 (2004) 361-365